A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
第3相
完了
NCT06238817
| 対象疾患 | Atopic Dermatitis |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Incyte Corporation |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 241 名 |
|---|
| 介入（薬剤） | Ruxolitinib Cream, Vehicle Cream |
|---|
| 開始日 | 2024年4月26日 |
|---|
| 完了日 | 2025年5月21日 |
|---|
| 結果公開日 | 2026年5月22日 |
|---|
概要
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8
Baseline; Week 8 · percentage of participants
| Vehicle Cream | 18.5 percentage of participants |
|---|
| Ruxolitinib 1.5% Cream | 70.0 percentage of participants |
|---|
| p-value | <0.0001 |
|---|
| Odds Ratio (OR) | 11.26 (95% CI 5.692–22.260) |
|---|
Percentage of Participants With Investigator's Global Assessment Treatment Success (IGA-TS) at Week 8
Baseline; Week 8 · percentage of participants
| Vehicle Cream | 13.6 percentage of participants |
|---|
| Ruxolitinib 1.5% Cream | 61.3 percentage of participants |
|---|
| p-value | <0.0001 |
|---|
| Odds Ratio (OR) | 10.14 (95% CI 4.904–20.975) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。